These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 8676471

  • 1. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA.
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [Abstract] [Full Text] [Related]

  • 2. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Parren PW, Burton DR.
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [Abstract] [Full Text] [Related]

  • 3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C.
    Virology; 1997 Mar 17; 229(2):360-9. PubMed ID: 9126249
    [Abstract] [Full Text] [Related]

  • 4. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC.
    J Virol; 2005 Jun 17; 79(11):6909-17. PubMed ID: 15890930
    [Abstract] [Full Text] [Related]

  • 5. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP.
    J Virol; 1994 Sep 17; 68(9):5854-62. PubMed ID: 7520095
    [Abstract] [Full Text] [Related]

  • 6. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    Warrier SV, Pinter A, Honnen WJ, Girard M, Muchmore E, Tilley SA.
    J Virol; 1994 Jul 17; 68(7):4636-42. PubMed ID: 7515975
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A, Blanco J, Krust B, Franco R, Hovanessian AG.
    J Virol; 1997 Nov 17; 71(11):8289-98. PubMed ID: 9343181
    [Abstract] [Full Text] [Related]

  • 8. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP, Ho DD.
    J Virol; 1993 Feb 17; 67(2):863-75. PubMed ID: 7678308
    [Abstract] [Full Text] [Related]

  • 9. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ, McInerney TL, McLain L, Wahren B, Hinkula J, Levi M, Dimmock NJ.
    J Gen Virol; 1996 Dec 17; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [Abstract] [Full Text] [Related]

  • 10. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA, Cordell J, Dean CJ, Balfe P.
    Virology; 1992 Dec 17; 191(2):732-42. PubMed ID: 1280382
    [Abstract] [Full Text] [Related]

  • 11. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.
    Tilley SA, Honnen WJ, Racho ME, Chou TC, Pinter A.
    AIDS Res Hum Retroviruses; 1992 Apr 17; 8(4):461-7. PubMed ID: 1376135
    [Abstract] [Full Text] [Related]

  • 12. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A.
    J Virol; 2007 Feb 17; 81(3):1424-32. PubMed ID: 17121806
    [Abstract] [Full Text] [Related]

  • 13. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J, Posner MR, Katinger H, Barbas CF, Burton DR, Chou TC, Ruprecht RM.
    AIDS Res Hum Retroviruses; 1997 May 20; 13(8):647-56. PubMed ID: 9168233
    [Abstract] [Full Text] [Related]

  • 14. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O, Tilley SA.
    J Virol; 1998 Jan 20; 72(1):286-93. PubMed ID: 9420226
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1.
    Vijh-Warrier S, Murphy E, Yokoyama I, Tilley SA.
    Mol Immunol; 1995 Oct 20; 32(14-15):1081-92. PubMed ID: 8544858
    [Abstract] [Full Text] [Related]

  • 16. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD, Schellekens MM, Abacioglu YH, Lewis GK, Tersmette M, Fouchier RA, Langedijk JP, Claassen E, Boersma WJ.
    J Virol; 1992 Mar 20; 66(3):1823-31. PubMed ID: 1637373
    [Abstract] [Full Text] [Related]

  • 17. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
    Matsushita S, Matsumi S, Yoshimura K, Morikita T, Murakami T, Takatsuki K.
    J Virol; 1995 Jun 20; 69(6):3333-40. PubMed ID: 7538171
    [Abstract] [Full Text] [Related]

  • 18. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
    Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE.
    J Virol; 2014 Nov 20; 88(21):12853-65. PubMed ID: 25165106
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.
    J Virol; 2004 Dec 20; 78(23):13232-52. PubMed ID: 15542675
    [Abstract] [Full Text] [Related]

  • 20. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S.
    J Virol; 2004 Mar 20; 78(5):2394-404. PubMed ID: 14963135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.